Q3 2024 Aurora Spine Corp Earnings Call Transcript
Key Points
- Aurora Spine Corp (ASAPF) achieved profitability with a net income of $71,000 for the third quarter of 2024, marking a significant turnaround from previous losses.
- The company reported a 21% increase in sales compared to Q3 2023, with total sales reaching $4.8 million, marking the fourth consecutive quarter of over $4 million in sales.
- Gross margin improved to 60% in Q3 2024, up from 59.7% in the same period last year, driven by increased sales of proprietary products with higher profitability.
- SiLO TFX sales grew by 35% from Q2 2024 to Q3 2024, reflecting successful expansion into the pain management market.
- Aurora Spine Corp (ASAPF) has successfully reduced operating expenses as a percentage of sales from 66% in Q3 2023 to 59% in Q3 2024, despite increased commissions and travel costs.
- Operating expenses increased to $2.81 million in Q3 2024, up from $2.61 million in Q2 2023, primarily due to increased commissions and travel costs.
- The company still faces challenges in expanding its sales force, as indicated by the need to part ways with some sales directors who did not meet goals.
- Despite the profitability, the net income of $71,000 is relatively modest, indicating that there is still room for improvement in financial performance.
- Aurora Spine Corp (ASAPF) has not yet received FDA approval for its facet system, which could delay potential revenue from this product.
- The company acknowledges the need to build more infrastructure and increase headcount to support expanded training programs and sales efforts.
Good day, and welcome to the Aurora Spine Third Quarter Financial Year 2024 Results Conference Call. (Operator Instructions) Please note, this event is being recorded.
Good morning, everyone, and thank you for joining us for the Aurora Spine Corporation quarterly earnings conference call. We look forward to discussing our performance for the third quarter of 2024.
Before diving into the details, I'd like to remind everyone that this call will contain forward-looking statements. These statements involve risk and uncertainty, and actual results could differ materially. For a full discussion on these risks, uncertainties, and factors, you are encouraged to read Aurora Spine's documents on file with SEDAR+, including those set forth in periodic reports filed under the forward-looking statements and Risk Factors section.
Statements made during the course of this call may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
